Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 239
interventional 160
Observational 66
Registry 13

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug|placebo 62
Drug 44
Other 22
Biological|placebo 5
Device 4
Procedure 4
Behavioral 3
Biological 3
Drug|Other 3
Device|Other 2
Diagnostic Test 2
Drug|placebo|Radiation 2
Biological|Drug 1
Device|Drug|Procedure 1
Diagnostic Test|Drug 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 59
United Kingdom 13
Germany 8
France 6
NA 5
Australia 3
Canada 3
Greece 3
Japan 3
Turkey 3
Belgium 2
China 2
Russian Federation 2
United States|Germany 2
Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|China|Czech Republic|France|Germany|Greece|Hungary|Ireland|Italy|Korea, Republic of|Mexico|Netherlands|Portugal|Russian Federation|South Africa|Spain|Taiwan|Turkey|United Kingdom 1
Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|China|Czechia|France|Germany|Greece|Hungary|Ireland|Italy|Mexico|Netherlands|Portugal|Russian Federation|Spain|United Kingdom 1
Australia|New Zealand 1
Belgium|Canada|Czechia|Egypt|Germany|Greece|Hungary|Israel|Italy|Netherlands|South Africa|Spain|Turkey 1
Belgium|Denmark|Finland|Germany|Italy|Netherlands|Spain|United Kingdom 1
Belgium|France|Germany|Italy|Netherlands|Spain|United Kingdom 1
Bulgaria|Croatia|Finland|France|Oman|Romania|Slovakia|Sweden|Ukraine 1
Canada|France|Ireland|Italy|Netherlands|Russian Federation 1
Hong Kong 1
Ireland 1
Netherlands 1
Spain 1
Sweden|Austria|Belgium|Denmark|France|Germany|Italy|United Kingdom 1
Switzerland 1
Taiwan 1
Ukraine|United Kingdom 1
United States|Argentina|Australia|Canada|Chile|Colombia|Czechia|Denmark|France|Germany|Greece|Israel|Italy|Korea, Republic of|Mexico|Portugal|Spain|Turkey|United Kingdom 1
United States|Argentina|Canada|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|South Africa 1
United States|Australia|Austria|Belgium|Canada|Croatia|Czech Republic|France|Germany|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Serbia|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada 1
United States|Australia|Belgium|Canada|Chile|China|Czechia|Finland|France|Germany|Greece|India|Ireland|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Portugal|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|Czech Republic|France|Germany|Ireland|Israel|Italy|Japan|Korea, Republic of|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|India|Italy|Japan|Korea, Republic of|Mexico|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Italy|Japan|Mexico|Peru|Poland|Spain|United Kingdom 1
United States|Australia|Belgium|Chile|Czechia|Denmark|Germany|Greece|Peru|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Belgium|China|Czech Republic|France|Germany|India|Ireland|Israel|Italy|Japan|United Kingdom 1
United States|Australia|Belgium|Czechia|Finland|France|Germany|Hungary|Japan|Korea, Republic of|Poland|Spain|United Kingdom 1
United States|Australia|Brazil|Canada|Colombia|Germany|Greece|Romania|Russian Federation|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Bulgaria|Canada|India|New Zealand|South Africa 1
United States|Australia|Canada|France|Germany|Israel|Italy|Slovenia|South Africa|Spain|Sweden|Turkey 1
United States|Australia|Chile|Colombia|Mexico|Peru 1
United States|Belgium 1
United States|Belgium|Canada|France|Germany|Israel|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|Canada|Germany|Netherlands 1
United States|Canada 1
United States|Canada|Chile|China|Finland|France|Germany|Greece|India|Japan|Korea, Republic of|Mexico|Netherlands|Portugal|Russian Federation|Spain|Turkey 1
United States|Canada|Chile|Mexico|Spain 1
United States|Canada|Denmark|France|Germany|Italy|Netherlands|Spain 1
United States|Canada|France|Germany|Ireland|Italy|United Kingdom 1
United States|Canada|France|Germany|Israel|Italy|Switzerland|United Kingdom 1
United States|Canada|France|Germany|Italy|Netherlands 1
United States|Canada|Turkey 1
United States|Czechia|Germany|Italy|Netherlands|Spain|Switzerland 1
United States|Germany|Japan|United Kingdom 1
United States|Hong Kong|Taiwan 1
United States|Netherlands 1

Sites per Study

Site_count Study_Count
1 80
2 6
3 3
4 4
5 4
6 1
7 3
8 5
9 1
10 4
11 5
12 1
13 2
15 1
17 1
18 2
19 1
21 1
23 2
25 1
26 1
27 1
29 1
30 2
31 1
32 1
36 2
37 1
38 1
42 1
50 1
53 1
56 1
58 1
61 1
69 1
72 1
79 1
85 1
86 1
92 1
94 1
98 1
101 1
108 1
112 1
113 1
117 1
132 1
173 1

Phase

Phase Study_Count
Phase 2 52
N/A 37
Phase 1 29
Phase 3 23
Phase 1/Phase 2 8
Phase 4 6
Early Phase 1 3
Phase 2/Phase 3 2

Number of Arms

Number_of_Arms Count_of_Studies
1 35
2 73
3 20
4 12
5 5
6 2
7 1
8 1
12 1
NA 10

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 10.00000 7.00000 8.00000 8.000 6.0000 120.0 25.0000 37.0000
1st Qu. 17.50000 22.00000 17.00000 17.250 35.7500 129.5 154.0000 93.0000
Median 25.00000 35.00000 25.00000 21.500 58.0000 139.0 340.0000 189.5000
Mean 23.33333 49.37838 36.75862 23.625 106.1731 139.0 386.3043 190.3333
3rd Qu. 30.00000 60.00000 40.00000 24.250 134.5000 148.5 553.0000 286.0000
Max. 35.00000 179.00000 120.00000 60.000 505.0000 158.0 1058.0000 347.0000

Trial Group Type

group_type Group_Count
Experimental 227
Placebo Comparator 71
Active Comparator 32
Other 12
NA 10
No Intervention 7
Sham Comparator 4

Intervention Model

intervention_model Study_Count
Parallel Assignment 92
Single Group Assignment 48
Crossover Assignment 15
Sequential Assignment 5

Primary Purpose

primary_purpose Study_Count
Treatment 129
Other 7
Diagnostic 6
Supportive Care 6
Basic Science 4
Health Services Research 3
Prevention 2
NA 2
Educational/Counseling/Training 1

Observational Studies

Studies by Country

Country Study_Count
United States 18
United Kingdom 9
France 6
Denmark 4
Germany 4
Canada 3
Greece 3
Italy 3
NA 2
Netherlands 2
Spain 2
Austria|Denmark|Finland|France|Germany|Ireland|Italy|Norway|Sweden|United Kingdom 1
Belgium 1
China 1
France|Italy|Netherlands 1
India 1
Japan 1
Sweden 1
Switzerland 1
Turkey 1
United States|Iceland 1

Sites per Study

Site_count Study_Count
1 45
2 3
3 2
4 3
5 1
7 3
8 2
9 2
17 1
18 1
26 1
31 1
106 1

Enrollment Metrics

Measure Observational
Min 12.0000
1st Qu 60.5000
Median 150.0000
Mean 947.1061
3rd Qu 437.5000
Max 20000.0000

Observation Model

observational_model Study_Count
Cohort 46
Case-Only 6
Case-Control 5
Other 4
Family-Based 3
Case-Crossover 1
Case Control 1

Time Perspective

time_perspective Study_Count
Prospective 49
Retrospective 7
Cross-Sectional 6
Other 4

Registries

Studies by Country

Country Study_Count
United States 4
Korea, Republic of 2
Austria|France|Germany|Italy|United Kingdom 1
Belgium|Luxembourg 1
China 1
Denmark 1
NA 1
United Kingdom 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 5
2 1
4 1
5 2
7 1
9 1
42 1
47 1

Enrollment Metrics

Measure Registries
Min 300.000
1st Qu 800.000
Median 1572.000
Mean 8967.077
3rd Qu 2000.000
Max 100000.000

Registry Model

observational_model Study_Count
Cohort 11
Case-Control 1
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 10
Other 2
Cross-Sectional 1

Follow-up

target_duration Study_Count
5 Years 5
10 Years 2
3 Years 2
15 Years 1
2 Years 1
20 Years 1
60 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04318704 Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough https://ClinicalTrials.gov/show/NCT04318704 Recruiting Algernon Pharmaceuticals 2021-03-31
NCT03326089 Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03326089 Recruiting Corfu General Hospital 2020-06-01
NCT03287414 Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03287414 Recruiting Novartis 2022-08-31
NCT03286556 Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03286556 Recruiting University of Alabama at Birmingham 2021-08-01
NCT03274544 Clinical Trial of Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT03274544 Recruiting The University of Hong Kong 2021-06-14
NCT03268915 Idiopathic Pulmonary Fibrosis (IPF) and the 3 Minutes Sit-to-stand Test https://ClinicalTrials.gov/show/NCT03268915 Completed University Hospital, Grenoble 2018-12-09
NCT03261037 A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period https://ClinicalTrials.gov/show/NCT03261037 Completed Hoffmann-La Roche 2019-11-27
NCT03229343 Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis. https://ClinicalTrials.gov/show/NCT03229343 Recruiting Assistance Publique - Hôpitaux de Paris 2020-02-29
NCT03222648 Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03222648 Recruiting University Hospital Southampton NHS Foundation Trust 2021-12-31
NCT03208933 Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). https://ClinicalTrials.gov/show/NCT03208933 Completed Hoffmann-La Roche 2019-11-13
NCT03183570 Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis and Primary Sclerosing Cholangitis Using PET/CT https://ClinicalTrials.gov/show/NCT03183570 Recruiting Stanford University 2021-04-14
NCT03142191 A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03142191 Recruiting Celgene 2021-06-30
NCT03104322 Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03104322 Completed patientMpower Ltd. 2018-03-09
NCT03050255 Short-term Effects of Supplemental Oxygen in Patients With IPF https://ClinicalTrials.gov/show/NCT03050255 Completed Schön Klinik Berchtesgadener Land 2018-03-31
NCT02951429 Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT02951429 Active, not recruiting Hoffmann-La Roche 2019-09-26
NCT02929017 Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers https://ClinicalTrials.gov/show/NCT02929017 Active, not recruiting University of Pittsburgh 2020-12-31
NCT02874989 Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial https://ClinicalTrials.gov/show/NCT02874989 Completed Wake Forest University Health Sciences 2019-06-03
NCT02871401 A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02871401 Active, not recruiting Vanderbilt University Medical Center 2019-12-31
NCT02802345 Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment https://ClinicalTrials.gov/show/NCT02802345 Completed Boehringer Ingelheim 2017-12-19
NCT02788474 Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment https://ClinicalTrials.gov/show/NCT02788474 Completed Boehringer Ingelheim 2017-08-04
NCT02759120 CleanUP IPF for the Pulmonary Trials Cooperative https://ClinicalTrials.gov/show/NCT02759120 Active, not recruiting Weill Medical College of Cornell University 2020-07-31
NCT02745184 Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02745184 Recruiting Shanghai East Hospital 2021-04-30
NCT02739165 Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02739165 Completed Asahi Kasei Pharma Corporation 2018-09-30
NCT02738801 Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 https://ClinicalTrials.gov/show/NCT02738801 Completed Galapagos NV 2017-05-02
NCT02707640 A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02707640 Completed Hoffmann-La Roche 2015-02-28
NCT02688647 A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02688647 Active, not recruiting Kadmon Corporation, LLC 2020-07-31
NCT02648048 A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02648048 Completed Hoffmann-La Roche 2016-11-30
NCT02612051 First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients https://ClinicalTrials.gov/show/NCT02612051 Completed GlaxoSmithKline 2016-06-02
NCT02606877 A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination https://ClinicalTrials.gov/show/NCT02606877 Completed Boehringer Ingelheim 2017-03-22
NCT02600689 Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02600689 Completed University of Alabama at Birmingham 2018-03-16
NCT02598193 Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02598193 Completed Hoffmann-La Roche 2017-05-16
NCT02594839 Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT02594839 Completed Federal Research Clinical Center of Federal Medical & Biological Agency, Russia 2018-01-31
NCT02594059 Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02594059 Recruiting Hopital Foch 2020-05-31
NCT02502097 A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) https://ClinicalTrials.gov/show/NCT02502097 Completed Afferent Pharmaceuticals, Inc. 2016-07-01
NCT02551068 High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib https://ClinicalTrials.gov/show/NCT02551068 Recruiting University of British Columbia 2022-04-30
NCT02550873 A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02550873 Active, not recruiting Promedior, Inc. 2018-05-02
NCT02538536 A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02538536 Completed ProMetic BioSciences Inc. 2017-01-31
NCT02503657 Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02503657 Active, not recruiting MediciNova 2020-12-31
NCT02477709 A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02477709 Completed Afferent Pharmaceuticals, Inc. 2015-08-07
NCT02460588 Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02460588 Completed Assistance Publique - Hôpitaux de Paris 2019-01-31
NCT02397005 Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects https://ClinicalTrials.gov/show/NCT02397005 Active, not recruiting Zai Lab Pty. Ltd. 2016-04-30
NCT02345070 Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02345070 Completed Sanofi 2017-05-22
NCT02268981 Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02268981 Completed Schön Klinik Berchtesgadener Land 2015-09-30
NCT02267655 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF https://ClinicalTrials.gov/show/NCT02267655 Completed Bellerophon 2017-06-30
NCT02257177 RCT (Randomized Control Trial) of TD139 vs Placebo in HV’s (Human Volunteers) and IPF Patients https://ClinicalTrials.gov/show/NCT02257177 Completed Galecto Biotech AB 2016-12-31
NCT02248064 Auto-titrating Oxygen in Chronic Respiratory Failure https://ClinicalTrials.gov/show/NCT02248064 Completed Imperial College London 2015-11-30
NCT02173145 Azithromycin in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02173145 Completed University Hospital Inselspital, Berne 2019-08-16
NCT02136992 Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02136992 Completed Shanghai Pulmonary Hospital, Shanghai, China 2013-06-30
NCT02085018 Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02085018 Completed Newcastle-upon-Tyne Hospitals NHS Trust 2016-09-27
NCT02058602 Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients https://ClinicalTrials.gov/show/NCT02058602 Completed GlaxoSmithKline 2016-07-11
NCT02048644 Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02048644 Completed Hull University Teaching Hospitals NHS Trust 2015-04-30
NCT02036970 Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT https://ClinicalTrials.gov/show/NCT02036970 Completed Reata Pharmaceuticals, Inc. 2018-01-19
NCT02019641 The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT02019641 Recruiting National Institutes of Health Clinical Center (CC) 2021-12-31
NCT02013700 Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) https://ClinicalTrials.gov/show/NCT02013700 Completed University of Miami 2015-12-11
NCT01979952 Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01979952 Completed Boehringer Ingelheim 2016-10-27
NCT01969409 Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01969409 Active, not recruiting University of Alabama at Birmingham 2019-01-31
NCT01919827 Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01919827 Completed Clinica Universidad de Navarra, Universidad de Navarra 2018-05-01
NCT01890265 Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01890265 Completed FibroGen 2017-07-28
NCT01872689 A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01872689 Completed Hoffmann-La Roche 2017-07-28
NCT01817686 Study of Default Options in Advance Directives https://ClinicalTrials.gov/show/NCT01817686 Completed Corporal Michael J. Crescenz VA Medical Center 2015-06-30
NCT01772667 Long Term Effects of an Inpatient Pulmonary Rehabilitation Program in Patients With Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01772667 Completed Schön Klinik Berchtesgadener Land 2016-06-30
NCT01766817 Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01766817 Completed Bristol-Myers Squibb 2016-02-29
NCT01725139 A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01725139 Completed GlaxoSmithKline 2016-07-12
NCT01637831 CPAP Therapy in Patients With Idiopathic Pulmonary Fibrosis and Sleep Apnea https://ClinicalTrials.gov/show/NCT01637831 Completed University of Crete 2011-09-30
NCT01619085 Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01619085 Active, not recruiting Boehringer Ingelheim 2017-07-05
NCT01529853 To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01529853 Completed Sanofi 2013-10-31
NCT01462006 Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01462006 Active, not recruiting University of Virginia 2018-11-30
NCT01442779 Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01442779 Completed Texas Tech University Health Sciences Center 2007-05-31
NCT01385644 A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01385644 Completed The Prince Charles Hospital 2013-05-31
NCT01371305 STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01371305 Completed Biogen 2017-03-31
NCT01366209 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01366209 Completed Genentech, Inc. 2014-02-28
NCT01362231 A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01362231 Completed Gilead Sciences 2012-12-31
NCT01335477 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II https://ClinicalTrials.gov/show/NCT01335477 Completed Boehringer Ingelheim 2013-10-31
NCT04396756 Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT04396756 Recruiting Pliant Therapeutics, Inc. 2021-12-31
NCT04326036 Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection https://ClinicalTrials.gov/show/NCT04326036 Enrolling by invitation Healeon Medical Inc 2021-11-01
NCT04233814 Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects https://ClinicalTrials.gov/show/NCT04233814 Recruiting Lung Therapeutics, Inc 2020-11-01
NCT04197791 Effect of Core Stabilization Exercises and Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT04197791 Active, not recruiting Istanbul University-Cerrahpasa 2020-11-30
NCT04196179 ANG-3070 in Healthy Adult Participants https://ClinicalTrials.gov/show/NCT04196179 Recruiting Angion Biomedica Corp 2020-08-31
NCT04072315 Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ https://ClinicalTrials.gov/show/NCT04072315 Recruiting Pliant Therapeutics, Inc. 2020-10-31
NCT04069143 Safety, Tolerability, Kinetics, and Repeatability of the Novel LPA1 PET Ligand 18F-BMS-986327 https://ClinicalTrials.gov/show/NCT04069143 Active, not recruiting Bristol-Myers Squibb 2020-07-16
NCT04030026 A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough https://ClinicalTrials.gov/show/NCT04030026 Active, not recruiting Trevi Therapeutics 2021-03-31
NCT03981406 Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03981406 Completed University of Minnesota 2019-03-01
NCT03981094 A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants https://ClinicalTrials.gov/show/NCT03981094 Completed Bristol-Myers Squibb 2019-07-27
NCT03979703 Yoga in Patients With Fibrosing Interstitial Lung Diseases https://ClinicalTrials.gov/show/NCT03979703 Recruiting Heidelberg University 2019-12-31
NCT03979430 Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study https://ClinicalTrials.gov/show/NCT03979430 Recruiting Heidelberg University 2020-07-30
NCT03955146 Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03955146 Recruiting FibroGen 2022-12-31
NCT03949530 A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03949530 Recruiting Indalo Therapeutics, Inc. 2020-06-30
NCT03928847 Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. https://ClinicalTrials.gov/show/NCT03928847 Recruiting University of California, San Francisco 2020-12-31
NCT03890250 Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03890250 Recruiting Biruni University 2020-03-01
NCT03832946 A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT03832946 Recruiting Galecto Biotech AB 2021-12-31
NCT03830125 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects https://ClinicalTrials.gov/show/NCT03830125 Completed Bridge Biotherapeutics, Inc. 2019-11-24
NCT03752892 Partitioned Training of Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03752892 Recruiting West Park Healthcare Centre 2021-03-31
NCT03733444 A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care https://ClinicalTrials.gov/show/NCT03733444 Recruiting Galapagos NV 2021-12-31
NCT03727802 Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03727802 Recruiting Toray Industries, Inc 2020-12-31
NCT03725852 A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT03725852 Active, not recruiting Galapagos NV 2020-07-31
NCT03717012 Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT03717012 Recruiting Boehringer Ingelheim 2020-06-15
NCT03711162 A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care https://ClinicalTrials.gov/show/NCT03711162 Recruiting Galapagos NV 2021-12-31
NCT03692481 Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving Pirfenidone https://ClinicalTrials.gov/show/NCT03692481 Recruiting Assistance Publique - Hôpitaux de Paris 2021-05-15
NCT03688334 Acute Effects of Oxygen Supplementation Among IPF Patients https://ClinicalTrials.gov/show/NCT03688334 Recruiting George Papanicolaou Hospital 2019-06-01
NCT03650075 To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers https://ClinicalTrials.gov/show/NCT03650075 Recruiting Metagone Biotech Inc. 2021-12-31
NCT03619616 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults https://ClinicalTrials.gov/show/NCT03619616 Completed Guangdong Zhongsheng Pharmaceutical Co., Ltd. 2019-06-28
NCT03584802 Therapeutic Plasma Exchange, Rituximab and IV Ig for Severe Acute Exacerbation of IPF Admitted in ICU https://ClinicalTrials.gov/show/NCT03584802 Recruiting Assistance Publique - Hôpitaux de Paris 2020-10-01
NCT03562416 Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects https://ClinicalTrials.gov/show/NCT03562416 Recruiting Temple University 2021-12-31
NCT03562247 Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT03562247 Recruiting Vanderbilt University Medical Center 2023-08-31
NCT03560154 Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT03560154 Active, not recruiting Istanbul University 2019-09-30
NCT03538301 JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF https://ClinicalTrials.gov/show/NCT03538301 Recruiting Nitto Denko Corporation 2021-07-31
NCT03535545 Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients https://ClinicalTrials.gov/show/NCT03535545 Recruiting Massachusetts General Hospital 2021-03-31
NCT03503188 Digital Auscultation Test - IPF Data Collection https://ClinicalTrials.gov/show/NCT03503188 Completed Boehringer Ingelheim 2019-01-03
NCT03500731 Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure https://ClinicalTrials.gov/show/NCT03500731 Recruiting University of Pittsburgh 2023-12-31
NCT03499275 Muscle Stimulation in Advanced Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03499275 Active, not recruiting Royal Brompton & Harefield NHS Foundation Trust 2020-03-31
NCT03477526 Status and Develepment Mental Quality of Life COPD/IPF Inpatients Before and After Pulmonary Rehabilitation https://ClinicalTrials.gov/show/NCT03477526 Recruiting Schön Klinik Berchtesgadener Land 2021-02-28
NCT03422068 This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated. https://ClinicalTrials.gov/show/NCT03422068 Completed Boehringer Ingelheim 2019-07-01
NCT03420235 Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life https://ClinicalTrials.gov/show/NCT03420235 Completed Erasmus Medical Center 2019-08-26
NCT03411876 Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03411876 Completed Schön Klinik Berchtesgadener Land 2019-01-15
NCT01266317 Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations https://ClinicalTrials.gov/show/NCT01266317 Completed University of Pittsburgh 2015-07-31
NCT01265888 Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. https://ClinicalTrials.gov/show/NCT01265888 Completed Geno LLC 2016-09-30
NCT01262001 Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01262001 Completed FibroGen 2014-06-26
NCT01254409 A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01254409 Completed Promedior, Inc. 2012-07-31
NCT01214187 Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01214187 Completed Brigham and Women’s Hospital 2014-10-31
NCT01199887 Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01199887 Completed ImmuneWorks 2012-10-31
NCT01170065 Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01170065 Completed Boehringer Ingelheim 2016-09-26
NCT01136174 Safety and PK Study of BIBF 1120 in Japanese Patients With IPF https://ClinicalTrials.gov/show/NCT01136174 Completed Boehringer Ingelheim 2011-03-31
NCT01118221 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients https://ClinicalTrials.gov/show/NCT01118221 Completed VA Office of Research and Development 2013-09-30
NCT00903331 Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study https://ClinicalTrials.gov/show/NCT00903331 Completed Actelion 2011-06-30
NCT00879879 Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00879879 Completed University of South Florida 2012-03-31
NCT02036580 D2212C00002 J-Phase II Study https://ClinicalTrials.gov/show/NCT02036580 Completed AstraZeneca 2015-11-30
NCT02846324 Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF https://ClinicalTrials.gov/show/NCT02846324 Completed Global Blood Therapeutics 2017-09-30
NCT02579603 Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF https://ClinicalTrials.gov/show/NCT02579603 Completed Boehringer Ingelheim 2017-01-03
NCT01457261 IPF Drug Deposition Study https://ClinicalTrials.gov/show/NCT01457261 Completed Royal Brompton & Harefield NHS Foundation Trust 2014-11-30
NCT01335464 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients https://ClinicalTrials.gov/show/NCT01335464 Completed Boehringer Ingelheim 2013-10-31
NCT00786201 A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00786201 Completed Centocor, Inc. 2012-01-31
NCT00705133 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00705133 Completed University of California, Los Angeles 2011-01-31
NCT00692796 Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00692796 Completed National Jewish Health 2010-03-31
NCT00662038 Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00662038 Completed Genentech, Inc. 2016-02-29
NCT00639496 Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00639496 Completed Zambon SpA 2003-07-31
NCT00631475 Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 https://ClinicalTrials.gov/show/NCT00631475 Completed Actelion 2010-04-30
NCT00600028 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide https://ClinicalTrials.gov/show/NCT00600028 Completed Johns Hopkins University 2011-09-30
NCT00563212 A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00563212 Completed NYU Langone Health 2010-06-01
NCT00532233 SD, IL-13 Production Rate in IPF https://ClinicalTrials.gov/show/NCT00532233 Completed Novartis 2009-06-30
NCT00517933 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00517933 Completed Duke University 2009-05-31
NCT00514683 Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00514683 Completed Boehringer Ingelheim 2010-06-30
NCT00463983 Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide https://ClinicalTrials.gov/show/NCT00463983 Completed Institut National de la Santé Et de la Recherche Médicale, France 2010-01-31
NCT00391443 BUILD 3: Bosentan Use in Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT00391443 Completed Actelion 2010-02-28
NCT00352482 Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT00352482 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00287729 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00287729 Completed Genentech, Inc. 2008-11-30
NCT00287716 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00287716 Completed Genentech, Inc. 2008-11-10
NCT00262405 Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00262405 Completed University of Michigan 2007-05-31
NCT00189176 Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00189176 Completed University of Michigan 2006-05-31
NCT00162760 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide https://ClinicalTrials.gov/show/NCT00162760 Completed Johns Hopkins University NA
NCT00131274 Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study https://ClinicalTrials.gov/show/NCT00131274 Completed Daniels, Craig E., M.D. NA
NCT00125385 Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00125385 Completed Sanofi 2008-09-30
NCT00109681 Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00109681 Completed Actelion 2006-10-31
NCT00105183 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection https://ClinicalTrials.gov/show/NCT00105183 Completed Neovii Biotech 2010-01-31
NCT00080223 Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00080223 Completed Genentech, Inc. 2015-04-30
NCT00074698 Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00074698 Completed FibroGen NA
NCT00071461 Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00071461 Completed Actelion 2005-09-30
NCT00063869 Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00063869 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2005-03-31
NCT00052052 An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00052052 Completed InterMune NA
NCT00047658 A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00047658 Completed InterMune NA
NCT00047645 A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00047645 Completed InterMune NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03300583 Toward Self-management in ILD https://ClinicalTrials.gov/show/NCT03300583 Recruiting Kingston University 2020-10-30
NCT03281200 Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain https://ClinicalTrials.gov/show/NCT03281200 Completed Boehringer Ingelheim 2018-06-07
NCT03211507 Idiopathic Pulmonary Fibrosis Job Exposures Study https://ClinicalTrials.gov/show/NCT03211507 Completed Imperial College London 2019-10-05
NCT03115619 Quality of Life Study in Participants With IPF Under Pirfenidone Treatment https://ClinicalTrials.gov/show/NCT03115619 Active, not recruiting Hoffmann-La Roche 2020-05-30
NCT02827734 Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD) https://ClinicalTrials.gov/show/NCT02827734 Recruiting Universitätsmedizin Mannheim 2020-12-31
NCT02818712 Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up https://ClinicalTrials.gov/show/NCT02818712 Active, not recruiting University of Aarhus 2021-03-31
NCT02803580 IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02803580 Completed Boehringer Ingelheim 2018-05-15
NCT02755441 Early Diagnosis of Pulmonary Fibrosis - Use of Biomarkers in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02755441 Recruiting University Hospital, Gentofte, Copenhagen 2022-12-31
NCT02632123 Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02632123 Recruiting Lawson Health Research Institute 2023-12-31
NCT02622477 Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone) https://ClinicalTrials.gov/show/NCT02622477 Completed Hoffmann-La Roche 2016-12-31
NCT02607722 All-Case Surveillance of Ofev in Patients With IPF in Japan https://ClinicalTrials.gov/show/NCT02607722 Recruiting Boehringer Ingelheim 2023-06-30
NCT02596841 Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias https://ClinicalTrials.gov/show/NCT02596841 Completed IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 2015-05-31
NCT03047031 Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03047031 Recruiting Boehringer Ingelheim 2021-12-31
NCT02552849 Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada https://ClinicalTrials.gov/show/NCT02552849 Completed Hoffmann-La Roche 2017-08-15
NCT02530736 Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02530736 Completed Royal Brompton & Harefield NHS Foundation Trust 2016-10-17
NCT03386994 OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study https://ClinicalTrials.gov/show/NCT03386994 Completed Boehringer Ingelheim 2019-09-16
NCT02445157 Reliability of the 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02445157 Completed Royal Brompton & Harefield NHS Foundation Trust 2015-08-31
NCT02437448 Breath Analysis in Lung Fibrosis https://ClinicalTrials.gov/show/NCT02437448 Active, not recruiting University of Zurich 2020-10-31
NCT02436278 The Predictive Ability of 4MGS in IPF https://ClinicalTrials.gov/show/NCT02436278 Completed Royal Brompton & Harefield NHS Foundation Trust 2017-10-20
NCT02151435 Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02151435 Completed University of Michigan 2017-07-31
NCT03360032 Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPF https://ClinicalTrials.gov/show/NCT03360032 Recruiting University Hospitals Coventry and Warwickshire NHS Trust 2020-04-30
NCT03478553 Genetics of IPF - Screening Study for Family Members https://ClinicalTrials.gov/show/NCT03478553 Recruiting University of Colorado, Denver 2021-09-29
NCT02009293 The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02009293 Completed Erasmus Medical Center 2016-12-31
NCT01777373 Conducting Airways in Lung Fibrosis (VACFI) https://ClinicalTrials.gov/show/NCT01777373 Completed Assistance Publique - Hôpitaux de Paris 2015-01-31
NCT01695408 Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01695408 Recruiting Technische Universität Dresden 2020-04-30
NCT04442711 Cohort of IPF Patients Experiencing an Exacerbation https://ClinicalTrials.gov/show/NCT04442711 Recruiting University Hospital, Gentofte, Copenhagen 2022-06-01
NCT04430491 To Evaluate the Use of Radiomics to Classify Between Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT04430491 Completed Maastricht University 2017-01-01
NCT04316780 Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes https://ClinicalTrials.gov/show/NCT04316780 Enrolling by invitation Steward St. Elizabeth’s Medical Center of Boston, Inc. 2019-12-31
NCT04257630 Coping Strategies Within Pulmonary Rehabilitation in Patients With IPF and COPD https://ClinicalTrials.gov/show/NCT04257630 Recruiting Schön Klinik Berchtesgadener Land 2022-03-31
NCT04187079 Immunopathologic Profiles and Blood Biomarkers in Patients With IPF https://ClinicalTrials.gov/show/NCT04187079 Active, not recruiting University of Aarhus 2019-05-01
NCT04177251 Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT04177251 Recruiting San Gerardo Hospital 2020-12-31
NCT04148157 Quality of Life in IPF - Patient and Physician Perceptions https://ClinicalTrials.gov/show/NCT04148157 Recruiting University of Washington 2020-03-01
NCT04031690 Health and Quality of Life Assessment Project for Caregivers of Idiopathic Pulmonary Fibrosis Patients https://ClinicalTrials.gov/show/NCT04031690 Recruiting Centre Hospitalier Universitaire Dijon 2021-10-31
NCT04019080 Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden https://ClinicalTrials.gov/show/NCT04019080 Recruiting Karolinska University Hospital 2021-12-31
NCT04016168 Idiopathic Pulmonary Fibrosis and Serum Bank https://ClinicalTrials.gov/show/NCT04016168 Recruiting Rennes University Hospital 2019-10-22
NCT03958071 A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking https://ClinicalTrials.gov/show/NCT03958071 Completed Boehringer Ingelheim 2019-05-31
NCT03944928 ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution https://ClinicalTrials.gov/show/NCT03944928 Recruiting University Hospital, Tours 2022-06-30
NCT03901196 Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy) https://ClinicalTrials.gov/show/NCT03901196 Recruiting University Hospital, Grenoble 2022-05-15
NCT03898284 Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03898284 Recruiting University Hospital, Tours 2021-12-31
NCT03770845 Nutritional Assessment in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03770845 Recruiting San Gerardo Hospital 2020-06-30
NCT03761082 Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy https://ClinicalTrials.gov/show/NCT03761082 Completed IlDong Pharmaceutical Co Ltd 2017-04-30
NCT03711435 Traditional Chinese Medicine(TCM) Syndrome Classification of Idiopathic Pulmonary Fibrosis(IPF) and Metabolomics https://ClinicalTrials.gov/show/NCT03711435 Completed Xuzhou Traditional Chinese Medicine Hospital 2020-02-05
NCT03710824 Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib https://ClinicalTrials.gov/show/NCT03710824 Recruiting Boehringer Ingelheim 2022-03-28
NCT03641742 Families-At-risk for Interstitial Lung Disease Study https://ClinicalTrials.gov/show/NCT03641742 Recruiting Columbia University 2035-10-01
NCT03588260 Respiratory Muscle Strength in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03588260 Active, not recruiting Istanbul Medipol University Hospital 2021-09-30
NCT03567785 Supporting Adherence to Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03567785 Recruiting KU Leuven 2021-06-30
NCT03457935 Detection of Early Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03457935 Recruiting Temple University 2020-12-31
NCT03437486 Mechanisms of Familial Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT03437486 Recruiting Vanderbilt University Medical Center 2021-04-30
NCT01150591 Microaspiration in Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01150591 Completed University of California, San Francisco 2015-06-30
NCT01134822 Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England) https://ClinicalTrials.gov/show/NCT01134822 Completed University of Nottingham 2017-09-05
NCT01110694 Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study https://ClinicalTrials.gov/show/NCT01110694 Completed Royal Brompton & Harefield NHS Foundation Trust 2018-09-30
NCT01107028 Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT01107028 Completed National Jewish Health 2014-10-31
NCT01088217 Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01088217 Recruiting National Jewish Health 2022-06-30
NCT01071707 Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT01071707 Completed University of Michigan 2011-08-31
NCT03836417 Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study https://ClinicalTrials.gov/show/NCT03836417 Recruiting Lawson Health Research Institute 2022-02-28
NCT03074149 Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF) https://ClinicalTrials.gov/show/NCT03074149 Active, not recruiting Boehringer Ingelheim 2021-04-30
NCT02699879 Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT02699879 Completed Hoffmann-La Roche 2016-09-15
NCT02630940 Exhaled Breath Condensate Biomarkers and Cough in IPF https://ClinicalTrials.gov/show/NCT02630940 Completed University of East Anglia 2016-06-30
NCT02315586 Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02315586 Recruiting National Institutes of Health Clinical Center (CC) 2021-12-31
NCT00512967 The Occurence of Inflammation and Oxidative Stress in Lung Diseases https://ClinicalTrials.gov/show/NCT00512967 Completed Maastricht University Medical Center NA
NCT00470327 A Study of the Natural Progression of Interstitial Lung Disease (ILD) https://ClinicalTrials.gov/show/NCT00470327 Recruiting University of Chicago 2020-12-31
NCT00453713 Race, Ethnicity, and Diffuse Parenchymal Lung Disease https://ClinicalTrials.gov/show/NCT00453713 Completed Columbia University 2013-08-31
NCT00373841 Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00373841 Recruiting University of Pittsburgh 2025-07-31
NCT00258570 Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00258570 Recruiting University of Pittsburgh 2025-07-31
NCT00258544 Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF) https://ClinicalTrials.gov/show/NCT00258544 Active, not recruiting University of Pittsburgh 2025-07-31
NCT00228670 Herpesvirus in Idiopathic Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00228670 Completed Emory University 2012-08-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03120481 Controls for Respiratory Diseases https://ClinicalTrials.gov/show/NCT03120481 Recruiting Seoul National University Hospital 2037-02-28
NCT02951416 Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank https://ClinicalTrials.gov/show/NCT02951416 Recruiting University of Giessen 2025-01-31
NCT02772549 Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay https://ClinicalTrials.gov/show/NCT02772549 Recruiting University Hospital, Gentofte, Copenhagen 2022-12-31
NCT02758808 Pulmonary Fibrosis Foundation Patient Registry https://ClinicalTrials.gov/show/NCT02758808 Recruiting University of Michigan 2021-03-31
NCT01915511 Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry https://ClinicalTrials.gov/show/NCT01915511 Recruiting Duke University 2025-01-31
NCT04263727 A Study of Patients With Chronic Disease https://ClinicalTrials.gov/show/NCT04263727 Recruiting Target PharmaSolutions, Inc. 2035-02-28
NCT04160715 Korean Idiopathic Pulmonary Fibrosis Registry https://ClinicalTrials.gov/show/NCT04160715 Recruiting Seoul National University Hospital 2025-01-31
NCT04016181 The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study https://ClinicalTrials.gov/show/NCT04016181 Enrolling by invitation University of Edinburgh 2022-03-31
NCT03747627 BPF Genetics of ILD Study https://ClinicalTrials.gov/show/NCT03747627 Recruiting NHS Forth Valley 2024-01-22
NCT03732859 PROOF-Registry New and Extended Belgium -Luxembourg https://ClinicalTrials.gov/show/NCT03732859 Recruiting Belgian Thoracic Society 2021-01-09
NCT03666234 Idiopathic Pulmonary Fibrosis Registry China Study https://ClinicalTrials.gov/show/NCT03666234 Recruiting China-Japan Friendship Hospital 2023-06-30
NCT00540475 Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry https://ClinicalTrials.gov/show/NCT00540475 Completed University of Pittsburgh 2018-07-31
NCT02407431 PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort https://ClinicalTrials.gov/show/NCT02407431 Active, not recruiting University of Pittsburgh 2020-09-30